NFKB1 and neoplasm: Moreover, NF-κB reporter assays and gel shift assays were done at several time points, from 12 to 25 days post-tumor cell inoculation, and at no time was there an activation of the reporter nor a significant increase in binding to an NF-κB oligonucleotide, unlike the robust increase we showed in a primary muscle inflammatory disease (Figure 7C) or in disuse atrophy [39].